BACKGROUND: @entity1 with @entity6 and @entity65 may not achieve adequate low-density lipoprotein @entity165 (LDL-C) lowering on statin monotherapy, attributed partly to @entity2299 . More intensive LDL-C-lowering therapy can be considered for these @entity1 . A previous randomized, controlled study demonstrated greater LDL-C lowering in @entity6 @entity1 with symptomatic @entity65 who switched from @entity3413 20 mg (S20) or @entity2993 10 mg (A10) to combination @entity3709 / @entity3413 10/20 mg (ES10/20) therapy, compared with @entity6817 dose-doubling (to S40 or A20) or switching to @entity8671 10 mg (R10). The effect of these regimens on novel biomarkers of @entity2299 (low- and high-density lipoprotein particle number and @entity6511 [ @entity6511 ]) was assessed. METHODS AND RESULTS: Treatment effects on low- and high-density lipoprotein particle number (by NMR) and @entity6511 (by ELISA) were evaluated using plasma samples available from 358 subjects in the study. Switching to ES10/20 reduced low-density lipoprotein-particle number numerically more than did statin dose-doubling and was comparable with R10 (-133.3, -94.4, and -56.3 nmol/L, respectively; P>0.05). Increases in high-density lipoprotein particle number were significantly greater with switches to ES10/20 versus statin dose-doubling (1.5 and -0.5  mol/L; P<0.05) and comparable with R10 (0.7  mol/L; P>0.05). Percentages of @entity1 attaining low-density lipoprotein particle number levels <990 nmol/L were 62.4% for ES10/20, 54.1% for statin dose-doubling, and 57.0% for R10. Switching to ES10/20 reduced @entity6511 activity significantly more than did statin dose-doubling (-28.0 versus -3.8 nmol/min per mL, P<0.05) and was comparable with R10 (-28.0 versus -18.6 nmol/min per mL; P>0.05); effects on @entity6511 concentration were modest. CONCLUSIONS: In @entity6 @entity1 with @entity2299 , switching from statins to combination ES10/20 therapy generally improved lipoprotein subclass profile and @entity6511 activity more than did statin dose-doubling and was comparable with R10, consistent with its lipid effects. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00862251.

Effect of Switching From Statin Monotherapy to @entity3709 / @entity3413 Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in @entity6 @entity1 With XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity3413 :: ('MESH:D019821', 'Chemical') :: ['simvastatin'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes mellitus'] @entity2299 :: ('MESH:D050171', 'Disease') :: ['dyslipidemia', 'atherogenic dyslipidemia'] @entity6817 :: ('D019821', 'Chemical') :: ['statin'] @entity2993 :: ('MESH:C065179', 'Chemical') :: ['atorvastatin'] @entity8671 :: ('MESH:C422923', 'Chemical') :: ['rosuvastatin'] @entity6511 :: ('7941', 'Gene') :: ['Lp-PLA2', 'lipoprotein-associated phospholipase A2'] @entity3709 :: ('MESH:C108606', 'Chemical') :: ['ezetimibe'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity65 :: (MESH:D002318,Disease) :: ['Symptomatic Cardiovascular Disease']
